Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-153M | $-145M | $-123M | -47.4% | -100.0% | -52.0% |
| 2024 | $87M | $-255M | $-302M | $-168M | -183.1% | -77.1% | -712.4% |
| 2023 | $381M | $40M | $49M | $11M | 11.4% | 1612.9% | -124.8% |
| 2022 | $22M | $-201M | $-198M | $-182M | -58.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expense | 153.29 |
| Research And Development | 90.40 |
| Selling General And Administration | 62.89 |
| Total Expenses | 153.29 |
| Operating Income | -153.29 |
| Total Operating Income As Reported | -153.29 |
| EBITDA | -152.77 |
| Normalized EBITDA | -152.77 |
| EBIT | -153.29 |
| Interest Income | 9.30 |
| Interest Expense | - |
| Net Interest Income | 9.30 |
| Other Non Operating Income Expenses | -0.70 |
| Other Income Expense | -0.70 |
| Interest Income Non Operating | 9.30 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 9.30 |
| Pretax Income | -144.69 |
| Tax Provision | 0.05 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -144.74 |
| Net Income From Continuing And Discontinued Operation | -144.74 |
| Net Income From Continuing Operation Net Minority Interest | -144.74 |
| Net Income | -144.74 |
| Net Income Common Stockholders | -144.74 |
| Net Income Including Noncontrolling Interests | -144.74 |
| Normalized Income | -144.74 |
| Diluted NI Availto Com Stockholders | -144.74 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 0.52 |
| Reconciled Cost Of Revenue | 0 |
| Total Unusual Items | 0 |
| Total Unusual Items Excluding Goodwill | 0 |
| Special Income Charges | 0 |
| Other Special Charges | - |
| Restructuring And Mergern Acquisition | 0 |
| General And Administrative Expense | - |
| Other Gand A | - |
| Other Operating Expenses | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc.this co. | AMLX | $1.6B | -10.99 | 5.21 | -47.4% | -8.97 |
| Innoviva, Inc. | INVA | $1.6B | 6.03 | 1.39 | 23.1% | 3.66 |
| Fortrea Holdings Inc. | FTRE | $1.6B | - | 2.90 | -175.0% | - |
| Capricor Therapeutics, Inc. | CAPR | $1.6B | -15.41 | 5.29 | -34.4% | -13.44 |
| Tyra Biosciences, Inc. | TYRA | $1.6B |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| -13.48 |
| 6.24 |
| -46.3% |
| -11.68 |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.6B | -5.59 | 24.71 | -441.6% | -7.18 |
| agilon health, inc. | AGL | $1.6B | - | 12.54 | -308.8% | - |
| Nurix Therapeutics, Inc. | NRIX | $1.6B | - | 2.93 | -49.1% | - |
| Sonida Senior Living, Inc. | SNDA | $1.6B | -22.19 | -142770.48 | 643445.5% | 96.78 |
| Peer Median | - | -13.48 | 4.11 | -47.7% | -7.18 | |